Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma.

Explore the efficacy and safety of mitoxantrone liposome combined with irinotecan and vincristine (VIM) in the treatment of relapsed/refractory soft tissue sarcoma in children.

Trial Details

NCT ID
NCT06514313
Phase
PHASE2
Sponsor
Yizhuo Zhang
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • Mitoxantrone Hydrochloride Liposome+Irinotecan+Vincristine
  • Temozolomide+Irinotecan+Vincristine
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • 2 years ≤age≤21 years, no gender limitation.
  • The Karnofsky (≥16 years old) or Lansky (\< 16 years old) physical status score is at least 70.
  • The expected survival time is not less than 12 weeks.
  • Heart function: a) Cardiac COLOR ultrasound detection LVEF≥ 50%; b) ECG suggests no myocardial ischemia; c) No history of arrhythmia requiring drug…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →